Cognition Operating Income from 2010 to 2025
| CGTX Stock | USD 0.49 0.04 8.89% |
Operating Income | First Reported 2020-03-31 | Previous Quarter -14.5 M | Current Value -7.7 M | Quarterly Volatility 4.1 M |
Check Cognition Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cognition Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 215.5 K, Interest Expense of 23.8 K or Selling General Administrative of 10.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.56. Cognition financial statements analysis is a perfect complement when working with Cognition Therapeutics Valuation or Volatility modules.
Cognition | Operating Income |
Latest Cognition Therapeutics' Operating Income Growth Pattern
Below is the plot of the Operating Income of Cognition Therapeutics over the last few years. Operating Income is the amount of profit realized from Cognition Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cognition Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Cognition Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cognition Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Cognition Operating Income Regression Statistics
| Arithmetic Mean | (26,826,269) | |
| Geometric Mean | 23,845,346 | |
| Coefficient Of Variation | (55.95) | |
| Mean Deviation | 12,421,495 | |
| Median | (17,831,000) | |
| Standard Deviation | 15,008,223 | |
| Sample Variance | 225.2T | |
| Range | 39.3M | |
| R-Value | (0.80) | |
| Mean Square Error | 86.2T | |
| R-Squared | 0.64 | |
| Significance | 0.0002 | |
| Slope | (2,527,657) | |
| Total Sum of Squares | 3378.7T |
Cognition Operating Income History
Other Fundumenentals of Cognition Therapeutics
Cognition Therapeutics Operating Income component correlations
Click cells to compare fundamentals
About Cognition Therapeutics Financial Statements
Cognition Therapeutics investors use historical fundamental indicators, such as Cognition Therapeutics' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cognition Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Income | -54 M | -56.7 M | |
| Non Operating Income Net Other | -31.5 K | -33.1 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.